Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cardiff Oncology (CRDF) Change in Accured Expenses (2016 - 2025)

Historic Change in Accured Expenses for Cardiff Oncology (CRDF) over the last 15 years, with Q3 2025 value amounting to -$2.0 million.

  • Cardiff Oncology's Change in Accured Expenses fell 19600000.0% to -$2.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.2 million, marking a year-over-year decrease of 3810.89%. This contributed to the annual value of $3.0 million for FY2024, which is 543.98% up from last year.
  • Latest data reveals that Cardiff Oncology reported Change in Accured Expenses of -$2.0 million as of Q3 2025, which was down 19600000.0% from $4.3 million recorded in Q2 2025.
  • Cardiff Oncology's Change in Accured Expenses' 5-year high stood at $4.3 million during Q2 2025, with a 5-year trough of -$2.0 million in Q3 2025.
  • Moreover, its 5-year median value for Change in Accured Expenses was $291000.0 (2021), whereas its average is $481315.8.
  • Per our database at Business Quant, Cardiff Oncology's Change in Accured Expenses soared by 600000.0% in 2023 and then tumbled by 19600000.0% in 2025.
  • Cardiff Oncology's Change in Accured Expenses (Quarter) stood at $1.5 million in 2021, then tumbled by 98.52% to $23000.0 in 2022, then surged by 6000.0% to $1.4 million in 2023, then plummeted by 35.99% to $898000.0 in 2024, then crashed by 318.37% to -$2.0 million in 2025.
  • Its last three reported values are -$2.0 million in Q3 2025, $4.3 million for Q2 2025, and -$1.0 million during Q1 2025.